This NMT Workstream was formed in 2021 to expand the PVRI community’s awareness and understanding of emerging device technologies for treating and diagnosing PH and RHF. It comprises experienced colleagues from academia, pharma, and regulatory fields, each with expertise in drug, device, and combination development.
Members aim to innovate and change current thinking, working in three sub-teams:
Inhalation Drug Delivery Technologies led by Nicholas Hill and Peter Fernandes
Therapeutic Device Technologies led by Marc Pritzker and John Scandurra
Monitoring of Diagnostic Device Technologies led by Alex Dusek, Veronica Franco and Alex Rothman
The Workstream is currently working on two manuscripts:
Inhalation technology advancements in treating RHF and PH
Advancements in the use of devices to treat PH
The group meets on the first Friday of each month at 15:00 BST/GMT. If you’re interested in joining this Workstream, please get in touch.
Our Regional Task Forces don't yet have global coverage. If you're interested in starting one, please contact us.
Interested in accessing global data on PH patient experience? Almost 4,000 patients and carers across 85 countries completed Phase 1 of our PH Global Patient Survey (PHGPS). Questions across all PH groups included diagnostic tests & timelines, genetic testing, treatments, financial burdens, hospital visits, research participation, quality of life, telemedicine, patient-reported outcome measures, and self-monitoring with digital technology. The findings have the potential to improve patient care, guide future research and help us address unmet needs.
